title: Essaven gel--review of experimental and clinical data.
abstract: Essaven gel (EG) has been developed for local treatment of venous and microcirculatory alterations (varicose veins, chronic venous insufficiency, associated signs and symptoms). Sport injuries (bruises, swelling secondary to sprains and contusions) respond favorably to EG, which is also indicated for varices in pregnancy. Active ingredients of EG are aescinate, sodium heparin, and essential phospholipids (EPL). The dose in 100 g of EG are: 1 g of aescinate, 10,000 IU of sodium heparin, and 1 g EPL. EG is applied several times daily in a thin film. Clinical reports on the activity of EG include several vascular applications in which the product is effective without contraindications or side effects. On the basis of this review, EG offers important therapeutic benefits to several types of patients and the product should be available for its usefulness and safety.
authors.affiliation: Department of Biomedical Sciences, Irvine2 Vascular Laboratory, Chieti University, Italy. cardres@pe.abol.it
authors.forename: G
authors.initials: G
authors.lastname: Belcaro
authors.forename: A N
authors.initials: AN
authors.lastname: Nicolaides
authors.forename: G
authors.initials: G
authors.lastname: Geroulakos
authors.forename: M R
authors.initials: MR
authors.lastname: Cesarone
authors.forename: L
authors.initials: L
authors.lastname: Incandela
authors.forename: M T
authors.initials: MT
authors.lastname: De Sanctis
mesh_terms: D004338:Drug Combinations; D004928:Escin / Q000032:analysis / Q000627:therapeutic use; D005343:Fibrinolytic Agents / Q000032:analysis / Q000627:therapeutic use; D006493:Heparin / Q000032:analysis / Q000627:therapeutic use; D006801:Humans; D010743:Phospholipids / Q000032:analysis / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; D005343:Fibrinolytic Agents; D010743:Phospholipids; D004928:Escin; C013980:Essaven Gel; D006493:Heparin